Karolinska Development AB, a Nordic life sciences investment company listed on Nasdaq Stockholm (KDEV), has announced that its portfolio company, AnaCardio, has raised SEK 205 million. This significant financial boost comes alongside the reporting of positive Phase 1b data for AC01, marking a pivotal moment in the development of innovative treatments for life-threatening or serious debilitating diseases.
Karolinska Development specializes in identifying and investing in breakthrough medical innovations within the Nordic region. The company collaborates with leading universities and research institutes, including the prestigious Karolinska Institutet, to support the growth of companies that aim to transform these innovations into commercial products. These products are designed not only to make a substantial difference in patients' lives but also to provide an attractive return on investment for shareholders.
With a portfolio of eleven companies, Karolinska Development is at the forefront of fostering advancements in the life sciences sector. The company is led by a team of seasoned investment professionals with a strong track record in building successful companies and a robust global network. This latest achievement by AnaCardio underscores Karolinska Development's commitment to supporting groundbreaking medical research and development.
